MedTrace Logo

Efficacy and Safety of DWJ1252 in the Treatment of Functional Dyspepsia (PART 2)

NCT03184402 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 124

Last updated 2019-06-26

No results posted yet for this study

Summary

The purpose of this study is to evaluate the Efficacy and Safety of DWJ1252 in treatment of Functional Dyspepsia.

Conditions

  • Functional Dyspepsia

Interventions

DRUG

DWJ1252

tablet

DRUG

Gasmotin

tablet

DRUG

Placebo of Gasmotin

tablet

DRUG

Placebo of DWJ1252

tablet

Sponsors & Collaborators

  • Daewoong Pharmaceutical Co. LTD.

    lead INDUSTRY

Principal Investigators

  • SMG-SNU BORAMAE MEDICAL CENTER · SMG-SNU Boramae Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-04-24
Primary Completion
2017-07-31
Completion
2017-07-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03184402 on ClinicalTrials.gov